PD-L2 expression in colorectal cancer: Independent prognostic effect and targetability by deglycosylation

Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm

(2017) Martin Rao et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

An Expanding Role for Immunotherapy in Colorectal Cancer

(2017) Katherine M. Bever et al.   Journal of the National Comprehensive Cancer Network

Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature

(2017) Laura Hickmott et al.   Targeted Oncology

Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade

(2017) Fei Zhang et al.   Cell Discovery

PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes

(2016) Matthew W Rosenbaum et al.   MODERN PATHOLOGY

Clinicopathologic profile, immunophenotype and genotype of CD274 (PD-L1)-positive colorectal carcinomas

(2016) Shingo Inaguma et al.   MODERN PATHOLOGY

Diet, microorganisms and their metabolites and colon cancer

(2016) Stephen J. D. O'Keefe   Nature Reviews Gastroenterology & Hepatology

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

(2016) Chia-Wei Li et al.   Nature Communications

Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma

(2016) Zheng Wang et al.   OncoImmunology

PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome

(2016) Joseph M. Obeid et al.   OncoImmunology

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

(2015) Willy Hugo et al.   CELL

Therapy-induced tumour secretomes promote resistance and tumour progression

(2015) Anna C. Obenauf et al.   NATURE

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma

(2015) S. Derks et al.   Cancer Immunology Research

Several immune escape patterns in non-Hodgkin's lymphomas

(2015) Camille Laurent et al.   OncoImmunology

Expression of Programmed Cell Death 1 Ligand 2 (PD-L2) Is a Distinguishing Feature of Primary Mediastinal (Thymic) Large B-cell Lymphoma and Associated With PDCD1LG2 Copy Gain

(2014) Min Shi et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Gene Set Enrichment Analysis (GSEA) of Toxoplasma gondii expression datasets links cell cycle progression and the bradyzoite developmental program

(2014) Matthew Croken et al.   BMC GENOMICS

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance

(2014) Yanping Xiao et al.   JOURNAL OF EXPERIMENTAL MEDICINE

ArhGAP30 promotes p53 acetylation and function in colorectal cancer

(2014) Jilin Wang et al.   Nature Communications

PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer

(2013) Minmin Song et al.   PLoS One

LAP+CD4+ T Cells Are Suppressors Accumulated in the Tumor Sites and Associated with the Progression of Colorectal Cancer

(2012) J. Mahalingam et al.   CLINICAL CANCER RESEARCH

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Smad4-Mediated Signaling Inhibits Intestinal Neoplasia by Inhibiting Expression of β-Catenin

(2011) Tanner J. Freeman et al.   GASTROENTEROLOGY

Experimentally Derived Metastasis Gene Expression Profile Predicts Recurrence and Death in Patients With Colon Cancer

(2009) J. Joshua Smith et al.   GASTROENTEROLOGY